Enliven Therapeutics, Inc. · NASDAQ:ELVN

Collins Helen Louise sold 5,000 Enliven Therapeutics, Inc. shares (Form 4)

Traded May 18, 2026 · Filed May 20, 2026

On May 18, 2026, Collins Helen Louise (CHIEF MEDICAL OFFICER) sold 5,000 Enliven Therapeutics, Inc. shares at an average US$39.79 for US$199K under a trading plan, leaving 25,000 shares. Filed May 20, 2026 (Form 4).

Sold
5,000 shares
Price
US$39.79 average (US$39.53 to US$41.21)
Value
US$199K
Holding after
25,000 shares
Trading plan
Yes (Made under a plan set in advance)
Role
CHIEF MEDICAL OFFICER

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
May 18, 2026Common StockOption exercise5,000US$2.4830,000Direct
May 18, 2026Common StockSale3,475US$39.5326,525Direct
May 18, 2026Common StockSale1,302US$40.2525,223Direct
May 18, 2026Common StockSale223US$41.2125,000Direct

Source

View original at SEC

Related